Azithromycin News and Research

RSS
Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
BESTCILIA project aims to improve screening, treatment of Primary Ciliary Dyskinesia

BESTCILIA project aims to improve screening, treatment of Primary Ciliary Dyskinesia

Diabetic patients taking oral fluoroquinolones may have high risk of severe blood sugar-related problems

Diabetic patients taking oral fluoroquinolones may have high risk of severe blood sugar-related problems

Study: Extended azithromycin therapy may offer significant benefits to COPD patients

Study: Extended azithromycin therapy may offer significant benefits to COPD patients

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Erythromycin may provide benefit for patients with non-CF bronchiectasis

Erythromycin may provide benefit for patients with non-CF bronchiectasis

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Disease eradication efforts set sights on polio, Guinea worm

Disease eradication efforts set sights on polio, Guinea worm

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

Positive results from Cempra's IV solithromycin Phase 1 study

Positive results from Cempra's IV solithromycin Phase 1 study

Tianyin Pharmaceutical sales decrease 26.9% to $69.6 million for fiscal year 2012

Tianyin Pharmaceutical sales decrease 26.9% to $69.6 million for fiscal year 2012

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

DuraSite 2 ophthalmic drug delivery system from InSite Vision

DuraSite 2 ophthalmic drug delivery system from InSite Vision

Promising new treatment for bronchiectasis

Promising new treatment for bronchiectasis

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

Azithromycin can be effective treatment option for patients with BOS

Azithromycin can be effective treatment option for patients with BOS